Does T-DXd + P Beat the CLEOPATRA Standard in First-Line Metastatic Disease?

40.7-month median PFS. DESTINY-Breast 09 challenges the long-standing standard of care in HER2+ metastatic breast cancer.

This clip breaks down why T-DXd + pertuzumab outperformed THP, what it means for first-line treatment, and how clinicians may individualize therapy moving forward.